title: A novel interaction between HER2/neu and cyclin E in breast cancer.
abstract: HER2/neu (HER2) and cyclin E are important prognostic indicators in breast cancer. As both are involved in cell cycle regulation we analyzed whether there was a direct interaction between the two. HER2 and cyclin E expression levels were determined in 395 breast cancer patients. Patients with HER2-overexpression and high levels of cyclin E had decreased 5-year disease-specific survival compared with low levels of cyclin E (14% versus 89%, P<0.0001). In vitro studies were performed in which HER2-mediated activity in HER2-overexpressing breast cancer cell lines was downregulated by transfection with HER2 small interfering RNA or treatment with trastuzumab. Cyclin E expression levels were determined by western blot analysis, and functional effects analyzed using kinase assays, MTT assays were used to assess cell viability as a marker of proliferation and fluorescence-activated cell sorting analysis was used to determine cell cycle profiles. Decreased HER2-mediated signaling resulted in decreased expression of cyclin E, particularly the low molecular weight (LMW) isoforms. Decreased HER2 and LMW cyclin E expression had functional consequences, including decreased cyclin E-associated kinase activity and decreased proliferation, because of increased apoptosis and an increased accumulation of cells in the G1 phase. In vivo studies performed in a HER2-overexpressing breast cancer xenograft model confirmed the effects of trastuzumab on cyclin E expression. Given the relationship between HER2 and cyclin E, in vitro clonogenic assays were performed to assess combination therapy targeting both proteins. Isobologram analysis showed a synergistic interaction between the two agents (trastuzumab targeting HER2 and roscovitine targeting cyclin E). Taken together, these studies show that HER2-mediated signaling effects LMW cyclin E expression, which in turn deregulates the cell cycle. LMW cyclin E has prognostic and predictive roles in HER2-overexpressing breast cancer, warranting further study of its potential as a therapeutic target.
authors.affiliation: Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: E A
authors.initials: EA
authors.lastname: Mittendorf
authors.forename: Y
authors.initials: Y
authors.lastname: Liu
authors.forename: S L
authors.initials: SL
authors.lastname: Tucker
authors.forename: T
authors.initials: T
authors.lastname: McKenzie
authors.forename: N
authors.initials: N
authors.lastname: Qiao
authors.forename: S
authors.initials: S
authors.lastname: Akli
authors.forename: A
authors.initials: A
authors.lastname: Biernacka
authors.forename: Y
authors.initials: Y
authors.lastname: Liu
authors.forename: L
authors.initials: L
authors.lastname: Meijer
authors.forename: K
authors.initials: K
authors.lastname: Keyomarsi
authors.forename: K K
authors.initials: KK
authors.lastname: Hunt
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D019927:Cyclin E / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D015536:Down-Regulation; D016193:G1 Phase / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D008970:Molecular Weight; D011485:Protein Binding; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D015996:Survival Rate; D014158:Transcription, Genetic; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019927:Cyclin E; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab
references.citation: J Exp Clin Cancer Res. 2006 Mar;25(1):59-64
references.pmid: 16761619
references.citation: Cell Cycle. 2006 Aug;5(15):1654-61
references.pmid: 16861913
references.citation: Mol Cell Biol. 2001 Sep;21(18):6254-69
references.pmid: 11509668
references.citation: J Clin Oncol. 1992 Jul;10(7):1049-56
references.pmid: 1351538
references.citation: Cancer Res. 1994 Jan 15;54(2):380-5
references.pmid: 7903908
references.citation: Cancer Res. 2002 Jul 15;62(14):4132-41
references.pmid: 12124352
references.citation: Science. 1993 Mar 26;259(5103):1908-12
references.pmid: 8384376
references.citation: Prog Cell Cycle Res. 1997;3:171-91
references.pmid: 9552414
references.citation: Cancer Res. 1989 Apr 15;49(8):2087-90
references.pmid: 2564806
references.citation: Cell Prolif. 2007 Aug;40(4):488-507
references.pmid: 17635517
references.citation: Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1112-6
references.pmid: 8430082
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: J Biol Chem. 2000 Aug 11;275(32):24735-9
references.pmid: 10859299
references.citation: Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S38-47
references.pmid: 14508079
references.citation: Oncogene. 1998 Nov 5;17(18):2393-402
references.pmid: 9811471
references.citation: Oncogene. 2000 Dec 11;19(53):6115-21
references.pmid: 11156524
references.citation: Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
references.pmid: 11252954
references.citation: Science. 1989 May 12;244(4905):707-12
references.pmid: 2470152
references.citation: Mol Cell Biol. 1995 May;15(5):2612-24
references.pmid: 7739542
references.citation: Nat Cell Biol. 2001 Mar;3(3):245-52
references.pmid: 11231573
references.citation: Cancer Res. 2000 Jan 15;60(2):481-9
references.pmid: 10667604
references.citation: Nature. 1999 Sep 16;401(6750):297-300
references.pmid: 10499591
references.citation: Cancer Res. 1991 Jun 15;51(12):3296-303
references.pmid: 1674898
references.citation: J Biol Chem. 2005 Apr 15;280(15):15148-57
references.pmid: 15708847
references.citation: J Clin Oncol. 2002 Feb 1;20(3):719-26
references.pmid: 11821453
references.citation: Cancer Res. 2004 May 1;64(9):3198-208
references.pmid: 15126360
references.citation: Oncogene. 2002 Sep 26;21(43):6573-86
references.pmid: 12242655
references.citation: Cancer Res. 1992 May 1;52(9):2580-9
references.pmid: 1373672
references.citation: Cancer Res. 2007 Aug 1;67(15):7212-22
references.pmid: 17671189
references.citation: N Engl J Med. 2002 Nov 14;347(20):1566-75
references.pmid: 12432043
references.citation: Cancer Res. 2008 Oct 1;68(19):7966-74
references.pmid: 18829554
references.citation: Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11034-8
references.pmid: 8248208
references.citation: Mol Cell Biol. 2000 Jan;20(2):672-83
references.pmid: 10611246
references.citation: Cancer Res. 2000 Feb 1;60(3):560-5
references.pmid: 10676637
references.citation: J Clin Oncol. 1999 Sep;17(9):2639-48
references.pmid: 10561337
references.citation: Oncogene. 1993 Aug;8(8):2127-33
references.pmid: 8336939